Last reviewed May 8, 2026
Quick answer: In 2025, the FDA acted to remove the class boxed (black box) warning from FDA-approved low-dose vaginal estrogen products including Estrace cream, Premarin cream, Estring, Vagifem, and Imvexxy. The action followed an FDA Advisory Committee vote of 17 to 1 in November 2024 recommending removal, and a decade-plus of petitioning by ACOG and NAMS. The original class warning, applied beginning in 1995 and expanded after the 2002 WHI, was based on systemic-HRT data that did not apply to low-dose local preparations producing blood estradiol levels under 20 pg/mL. As a 2024 BMJ Editorial argued, the misapplied warning had been driving treatment avoidance for women with moderate-to-severe genitourinary syndrome of menopause (GSM).
60-second TL;DR
What actually changed in 2025
The FDA's 2025 action removed the class boxed warning from the labels of FDA-approved low-dose vaginal estrogen products. Boxed warnings — informally known as "black box" warnings — are the strongest safety statement the FDA can require on a prescription label, signaling significant or life-threatening adverse reactions. The class warning had been applied to all estrogen products since 1995 and expanded after the 2002 Women's Health Initiative published its data on oral combination HRT.
The 2025 update did three things: removed the boxed warning section from low-dose vaginal estrogen labels; retained product-specific contraindications (active breast cancer, undiagnosed vaginal bleeding, active thrombosis); and added an unboxed information note that the systemic risks observed with oral HRT have not been observed with low-dose vaginal preparations at recommended doses. ACOG and NAMS published parallel patient-education updates in 2025 reflecting the change.
The 30-year timeline
1995 — class boxed warning applied
FDA applies a boxed warning to estrogen products following data linking unopposed estrogen to endometrial cancer in women with an intact uterus. The warning is applied as a class label across all estrogen formulations, including low-dose vaginal preparations.
2002 — Women's Health Initiative published
JAMA publishes the WHI estrogen-plus-progestin arm results. Half of US HRT prescriptions disappear within 12 months. The boxed warning is expanded in subsequent labeling cycles to reference the WHI cardiovascular and breast cancer data.
2014 — ACOG citizen petition
ACOG petitions the FDA to revise the boxed warning on low-dose vaginal estrogen, arguing the warning is not supported by the data on local preparations. The petition is supported by NAMS and the Endocrine Society.
2017 — NAMS Position Statement on GSM
NAMS publishes a Position Statement on the Treatment of GSM stating that low-dose vaginal estrogen is first-line and that the boxed warning is not consistent with the safety data. The statement is widely cited in subsequent FDA correspondence.
2022 — NAMS Hormone Therapy Position Statement
NAMS publishes its full updated Hormone Therapy Position Statement, reaffirming that low-dose vaginal estrogen carries a different safety profile from systemic HRT and reiterating that labeling should reflect the evidence.
2024 — FDA Advisory Committee vote: 17–1
In November 2024, an FDA Advisory Committee votes 17 to 1 in favor of removing the class boxed warning from low-dose vaginal estrogen. The committee finds the warning is not scientifically supported for these products and is driving treatment avoidance for moderate-to-severe GSM.
2024 — BMJ Editorial
A BMJ Editorial in late 2024 makes the public-health argument for removing the warning, citing data that millions of postmenopausal women with GSM go untreated in part because of clinician hesitation tied to the boxed warning.
2025 — FDA action: boxed warning removed
The FDA acts on the Advisory Committee recommendation. Updated labels for FDA-approved low-dose vaginal estrogen products (Estrace, Premarin, Estring, Vagifem, Imvexxy) no longer carry the boxed warning. ACOG and NAMS publish patient-facing updates.
2026 — practical implementation
Updated label is in pharmacy distribution. Patient-facing materials at major medical centers (Mayo, Cleveland Clinic) reflect the change. Treatment avoidance is expected to decline gradually as primary care clinicians update their prescribing patterns.
"The boxed warning was the wrong warning, in the wrong place, on the wrong dose — for thirty years. Removing it is overdue, not radical." — ClearedRx Medical Network, paraphrasing 2024 BMJ Editorial
Why the warning was removed: the actual evidence
The original boxed warning was scientifically defensible for systemic estrogen therapy (oral pills, high-dose patches) where blood estrogen levels reach 50 to 100 pg/mL. It was never well supported for low-dose vaginal preparations, where blood estradiol levels stay under 20 pg/mL — within the postmenopausal range and below the levels associated with the WHI cardiovascular and breast cancer signals.
Multiple lines of evidence converged on the conclusion. Pharmacokinetic data showed minimal systemic absorption from low-dose vaginal preparations. Observational cohort studies — including NIH-funded long-term safety analyses — showed no increase in cardiovascular events, venous thromboembolism, or breast cancer in women using low-dose vaginal estrogen. A 2018 analysis of the WHI Observational Study, frequently cited in FDA briefing materials, found no increase in any of these outcomes among long-term users of vaginal estrogen.
The 2024 Advisory Committee briefing materials referenced these data lines explicitly. The 17-to-1 vote reflected what most menopause specialists had been saying for over a decade: the warning didn't fit the medication.
What it means for patients in 2026
The practical impact in 2026 is expected to play out gradually. Primary care clinicians who had been hesitant to prescribe vaginal estrogen — even for women with moderate-to-severe GSM — now have less labeling-based reason to hesitate. Patients reading the package insert no longer see the boxed warning that, for many, had been the sole reason they declined a clinically appropriate treatment.
Specifically:
- Patients with severe GSM — recurrent UTIs, painful sex, ongoing dryness despite OTC moisturizers — who had been told "you can't take estrogen" should bring the 2025 update to their primary care visit.
- Breast cancer survivors — the conversation with the oncology team remains the same per ACOG Committee Opinion 659; the boxed warning change does not eliminate that individualized decision-making.
- Women on aromatase inhibitors — the AI-specific considerations remain. The boxed warning change is about general labeling, not AI-specific risk assessment.
- Telehealth-prescribed vaginal estrogen — the change reduces clinical hesitation among prescribers in services like ClearedRx, Midi, Evernow, and others. The underlying evidence base hasn't changed; the labeling now matches it.
Where compounded vaginal estrogen fits
The FDA's 2025 boxed warning removal is specifically about FDA-approved finished products, since the FDA regulates the label on those products. Compounded estradiol vaginal cream, prepared per prescription by a state-licensed 503A pharmacy, uses the same estradiol molecule. Compounded preparations are not separately FDA-approved as finished products and don't carry the same labeled warnings — but the underlying clinical evidence on safety profile applies to the molecule, not to the regulatory pathway.
In practice: a clinician who is now more comfortable prescribing FDA-approved Estrace because of the 2025 label change is also more comfortable prescribing a compounded estradiol cream from a 503A pharmacy. The molecule is the same; the dose is the same; the underlying safety data is the same. ClearedRx prescribes both and selects the route that fits the patient (cost, allergens, custom strength). For a deeper look at the compounded vs FDA-approved decision, see our compounded vs FDA-approved explainer.
What the change does NOT eliminate
The boxed warning removal narrows the labeling but does not change individual clinical decision-making in a few important areas:
- Active or recent breast cancer — vaginal estrogen remains a careful, individualized decision per ACOG Committee Opinion 659. The boxed warning was never the deciding factor for this group; the underlying clinical considerations still apply.
- Undiagnosed vaginal bleeding — must be evaluated before starting any estrogen.
- Active thromboembolism — clinicians remain cautious. Low-dose vaginal preparations have minimal systemic effect, but individual decisions are still made with the full clinical picture.
- Compounded pellet HRT — a separate compounding category that operates outside this discussion. ACOG and NAMS apply more caution to pellets than to creams or oral compounding, and the FDA boxed-warning change does not address pellets.
The bottom line
Frequently asked questions
Did the FDA remove the black box warning from vaginal estrogen?
Yes — in 2025, following a November 2024 Advisory Committee vote of 17 to 1. Updated labels for Estrace cream, Premarin cream, Estring, Vagifem, and Imvexxy no longer carry the boxed warning.
Why was the warning removed?
It was a class warning applied across all estrogen products since 1995 and expanded after the 2002 WHI. The data behind it came from systemic HRT trials and didn't apply to low-dose vaginal preparations, which produce blood estradiol under 20 pg/mL. ACOG petitioned starting 2014; NAMS supported; the Advisory Committee found the warning scientifically unsupported and a driver of treatment avoidance.
What does the new label look like?
No boxed warning section. Product-specific contraindications retained (active breast cancer, undiagnosed bleeding, active thrombosis). Unboxed information note that systemic risks observed with oral HRT were not seen with low-dose vaginal preparations.
What does this mean for patients in 2026?
Less clinical hesitation. Primary care clinicians who had been declining to prescribe vaginal estrogen because of the boxed warning have less reason to do so. Patients reading the insert no longer see the warning that had been driving discontinuation.
Does this apply to compounded vaginal estrogen?
The labeling action applies to FDA-approved products. Compounded estradiol vaginal cream uses the same molecule and the same safety evidence base, but is prepared per prescription by a 503A pharmacy and doesn't carry FDA labeling. The clinical decision-making is similar.
What was the 1995 history of the boxed warning?
Class warning first applied based on endometrial cancer signal in unopposed estrogen use in women with intact uteri. Expanded after 2002 WHI to reference cardiovascular and breast cancer signals from oral combination HRT. Class label applied to all estrogen products including low-dose vaginal preparations.
How does ClearedRx fit into this update?
ClearedRx prescribes both FDA-approved options (now without the boxed warning) and a flat $89/month compounded estradiol cream. The 2025 change directly reduces clinical hesitation in async telehealth prescribing.
Where can I read the FDA's action letter?
FDA Drug Safety Communications and labeling change announcements at fda.gov/drugs/drug-safety-and-availability. November 2024 Advisory Committee briefing documents archived in the FDA Advisory Committee Materials. ACOG and NAMS published patient-facing summaries on their public websites.
Considering vaginal estrogen in 2026?
Tell a ClearedRx prescriber your symptoms in writing. They'll recommend FDA-approved generic estradiol cream, brand-name Estrace or Estring, or our flat $89/month compounded option — based on what fits. Discreet shipping in 50 states.
Start my private review
